47.8K
Downloads
75
Episodes
AllergyTalk is a round-up of the latest in the field of allergy and immunology by the American College of Allergy, Asthma and Immunology. In each bi-monthly episode, hosts Gerald Lee, MD, and Merin Kalangara, MD, invite a guest to discuss key articles reviewed in the current issue of AllergyWatch.
Episodes
Wednesday Oct 02, 2019
Wednesday Oct 02, 2019
For today’s episode we will be reviewing three articles from the July-August 2019 issue of Allergy Watch:
https://www.ncbi.nlm.nih.gov/pubmed/30488542
https://www.ncbi.nlm.nih.gov/pubmed/30170124
https://www.ncbi.nlm.nih.gov/pubmed/30684739
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee was on an advisory board for Teva.
Dr. Kalangara has received consulting fees from AstraZeneca.
Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.
Comments (0)
To leave or reply to comments, please download free Podbean or
No Comments
To leave or reply to comments,
please download free Podbean App.